705 related articles for article (PubMed ID: 28843110)
1. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab.
Jain T; John J; Kotecha A; Deol A; Saliminia T; Revankar S; Chandrasekar P
Ann Hematol; 2016 Aug; 95(8):1323-7. PubMed ID: 27225264
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
Marchesi F; Pimpinelli F; Dessanti ML; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Maschio M; Ensoli F; Mengarelli A
Transpl Infect Dis; 2014 Dec; 16(6):1032-8. PubMed ID: 25369809
[TBL] [Abstract][Full Text] [Related]
4. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
Kim JH; Goulston C; Sanders S; Lampas M; Zangari M; Tricot G; Hanson KE
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1753-8. PubMed ID: 22728249
[TBL] [Abstract][Full Text] [Related]
6. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
Marchesi F; Mengarelli A; Giannotti F; Tendas A; Anaclerico B; Porrini R; Picardi A; Cerchiara E; Dentamaro T; Chierichini A; Romeo A; Cudillo L; Montefusco E; Tirindelli MC; De Fabritiis P; Annino L; Petti MC; Monarca B; Arcese W; Avvisati G;
Transpl Infect Dis; 2014 Feb; 16(1):158-64. PubMed ID: 24215479
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center study.
Marchesi F; Pimpinelli F; Gumenyuk S; Renzi D; Palombi F; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Ensoli F; Mengarelli A
World J Transplant; 2015 Sep; 5(3):129-36. PubMed ID: 26421265
[TBL] [Abstract][Full Text] [Related]
9. Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?
Kaya AH; Tekgunduz E; Akpinar S; Batgi H; Bekdemir F; Kayikci O; Namdaroglu S; Ulu BU; Dal MS; Cakar MK; Korkmaz S; Altuntas F
Transplant Proc; 2017 Oct; 49(8):1911-1915. PubMed ID: 28923647
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program.
Rossini F; Terruzzi E; Cammarota S; Morini F; Fumagalli M; Verga L; Elli E; Verga M; Miccolis I; Parma M; Pogliani EM
Transpl Infect Dis; 2005; 7(3-4):122-5. PubMed ID: 16390400
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus reactivation in patients with multiple myeloma.
Hasegawa T; Aisa Y; Shimazaki K; Ito C; Nakazato T
Eur J Haematol; 2016 Jan; 96(1):78-82. PubMed ID: 25810117
[TBL] [Abstract][Full Text] [Related]
14. Prognostic outcomes of cytomegalovirus reactivation after autologous stem cell transplantation.
Lee BH; Jeon MJ; Yu ES; Kang KW; Kim DS; Lee SR; Park Y; Sung HJ; Choi CW; Kim BS
Int J Med Sci; 2023; 20(2):186-193. PubMed ID: 36794152
[No Abstract] [Full Text] [Related]
15. Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring.
Yong MK; Ananda-Rajah M; Cameron PU; Morrissey CO; Spencer A; Ritchie D; Cheng AC; Lewin SR; Slavin M
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1961-1967. PubMed ID: 28797778
[TBL] [Abstract][Full Text] [Related]
16. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
[TBL] [Abstract][Full Text] [Related]
17. Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients.
Annibali O; Piccioni L; Tomarchio V; Circhetta E; Sarlo C; Franceschini L; Cantonetti M; Rizzo E; Angeletti S; Tirindelli MC; Scagnolari C; Statzu M; Avvisati G; Riva E
PLoS One; 2018; 13(7):e0200221. PubMed ID: 30036376
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus reactivation following hematopoietic stem cell transplantation.
Sharma SK; Kumar S; Agrawal N; Singh L; Mukherjee A; Seth T; Mishra P; Mathur S; Dar L; Mahapatra M
J Infect Dev Ctries; 2013 Dec; 7(12):1003-7. PubMed ID: 24334950
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk factors for cytomegalovirus (CMV) reactivation following autologous hematopoietic stem cell transplantation in children.
Hussein AA; Al-Antary ET; Najjar R; Al-Hamdan DS; Al-Zaben A; Frangoul H
Pediatr Blood Cancer; 2015 Jun; 62(6):1099-101. PubMed ID: 25346146
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K
Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
